Loading...
•
Oct 31, 2023
KalVista Q2 2024 Earnings Report
KalVista reported second fiscal quarter results and provided an operational update.
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the quarter ended October 31, 2023. The company's net loss was $27.7 million, or $(0.80) per share. Cash, cash equivalents and marketable securities were $103.2 million as of October 31, 2023. The KONFIDENT trial achieved the targeted number of attacks to complete the trial.
Achieved the targeted number of on-treatment attacks required to complete the phase 3 KONFIDENT trial, with topline data expected in early 2024 and NDA submission in the first half of 2024.
Received Orphan Drug Status (ODS) approval from Switzerland for sebetralstat.
Presented real-world patient data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
Conducted fireside chats at the Cantor Global Healthcare Conference, Stifel 2023 Healthcare Conference, and Jefferies London Healthcare Conference.
Forward Guidance
KalVista anticipates providing data from the phase 3 KONFIDENT clinical trial in early 2024 and expects to file for approval in the European Union and Japan later in 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...